Patrick Vermersch
Impact in
- Pathology and Forensic Medicine top 0.02%
- Multiple Sclerosis Research Studies
- Neurology top 0.5%
- Cerebrovascular and genetic disorders
- Myasthenia Gravis and Thymoma
Papers in
-
- Multiple Sclerosis Research Studies 370
- Neurology 51
- Peripheral Neuropathies and Disorders 18
- Co-authors
- Jerome De Seze (141 shared papers)Didier Leys (21 shared papers)Tanya Stojkovic (80 shared papers)Jean‐Pierre Pruvo (36 shared papers)Hélène Zéphir (78 shared papers)Frederik Barkhof (24 shared papers)M Steinling (5 shared papers)Philip Scheltens (8 shared papers)
- Journals
- Neurology (82 papers)Multiple Sclerosis Journal (54 papers)Multiple Sclerosis and Related Disorders (33 papers)Journal of Neurology (22 papers)Journal of the Neurological Sciences (16 papers)
- Partner nations
- FranceGermanyUnited States
In The Last Decade
Patrick Vermersch
533 papers receiving 22k citations
Patrick Vermersch's Hit Papers
Peers
Comparison fields: 5 of 149
- Pathology and Forensic Medicine 12.6k
- Neurology 2.5k
- Psychiatry and Mental health 2.6k
- Ophthalmology 757
- Physiology 1.8k
Countries citing papers authored by Patrick Vermersch
This map shows the geographic impact of Patrick Vermersch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Vermersch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Vermersch more than expected).
Fields of papers citing papers by Patrick Vermersch
This network shows the impact of papers produced by Patrick Vermersch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Vermersch. The network helps show where Patrick Vermersch may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick Vermersch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 558 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. Hit paper breakdown → | 1992 | 1440 |
| 2 | A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging Hit paper breakdown → | 1993 | 831 |
| 3 | A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis Hit paper breakdown → | 2010 | 804 |
| 4 | Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Hit paper breakdown → | 2018 | 747 |
| 5 | The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease Hit paper breakdown → | 1999 | 674 |
| 6 | Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study Hit paper breakdown → | 2017 | 632 |
| 7 | Neuromyelitis Optica and Non–Organ-Specific Autoimmunity Hit paper breakdown → | 2008 | 502 |
| 8 | 2004 | 500 | |
| 9 | Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis Hit paper breakdown → | 2010 | 489 |
| 10 | 2007 | 486 | |
| 11 | Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis Hit paper breakdown → | 2017 | 474 |
| 12 | Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults Hit paper breakdown → | 2018 | 455 |
| 13 | Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension Hit paper breakdown → | 2018 | 286 |
| 14 | Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study Hit paper breakdown → | 2016 | 285 |
| 15 | Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study Hit paper breakdown → | 2017 | 284 |
| 16 | 1995 | 277 | |
| 17 | 2013 | 276 | |
| 18 | 2014 | 270 | |
| 19 | 2014 | 263 | |
| 20 | 2014 | 214 |
About Patrick Vermersch
Patrick Vermersch is a scholar working on Pathology and Forensic Medicine, Neurology, Physiology, Psychiatry and Mental health and Oncology, having authored 558 papers that have together received 22.9k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (370 papers), Alzheimer's disease research and treatments (19 papers), Polyomavirus and related diseases (19 papers), Peripheral Neuropathies and Disorders (18 papers), Dementia and Cognitive Impairment Research (15 papers), Hereditary Neurological Disorders (10 papers), Muscle Physiology and Disorders (9 papers) and Salivary Gland Disorders and Functions (8 papers). The work is most often cited by research in Pathology and Forensic Medicine (12.6k citations), Neurology (2.5k citations), Psychiatry and Mental health (2.6k citations), Ophthalmology (757 citations) and Physiology (1.8k citations). Patrick Vermersch has collaborated with scholars based in France, Germany and United States. Frequent co-authors include Jerome De Seze, Didier Leys, Tanya Stojkovic, Jean‐Pierre Pruvo, Hélène Zéphir, Frederik Barkhof, M Steinling, Philip Scheltens, Jacob Valk and Gavin Giovannoni. Their work appears in journals such as Neurology, Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders, Journal of Neurology and Journal of the Neurological Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.